• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2012 Product Image

Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2012

  • ID: 2335145
  • November 2012
  • 49 pages
  • Global Markets Direct

Genital Warts (Condylomata Acuminata) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Genital Warts (Condylomata Acuminata) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Genital Warts (Condylomata Acuminata), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Genital Warts (Condylomata Acuminata). Genital Warts (Condylomata Acuminata) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Genital Warts (Condylomata READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Genital Warts (Condylomata Acuminata) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Genital Warts (Condylomata Acuminata) 7
Genital Warts (Condylomata Acuminata) Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Genital Warts (Condylomata Acuminata) Therapeutics – Products under Development by Companies 14
Companies Involved in Genital Warts (Condylomata Acuminata) Therapeutics Development 15
Helix BioPharma Corp. 15
Inovio Biomedical Corporation 16
MediGene AG 17
Anaconda Pharma 18
Telormedix SA 19
Genetic Immunity, LLC 20
Moberg Derma AB 21
Genital Warts (Condylomata Acuminata) – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
interferon alpha-2b - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Veregen - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
TMX-202 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
HupaDerm Vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
imiquimod - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AP-611074 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SynCon HPV Vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Genital Warts (Condylomata Acuminata) Therapeutics – Drug Profile Updates 35
Genital Warts (Condylomata Acuminata) Therapeutics - Dormant Products 40
Genital Warts (Condylomata Acuminata) – Product Development Milestones 41
Featured News & Press Releases 41
Jan 26, 2012: Hemispherx Biopharma Gains Regulatory Approval In Latin America For Alferon N Injection 41
Jan 25, 2012: Kaiser Permanente Study Finds Gardasil Does Not Trigger Lupus, Rheumatoid Arthritis Or Type 1 Diabetes After Vaccination 41
Jan 19, 2012: National Advisory Committee On Immunization Recommends Merck's GARDASIL 42
Dec 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions 43
Nov 15, 2011: Moberg Derma Receives SEK4m From Vinnova For Development Of Limtop 44
Aug 17, 2011: Hemispherx Biopharma Submits Regulatory Approval For Alferon In Argentina 44
Jul 01, 2011: Merck Receives Approval To Market GARDASIL In Japan 45
Apr 26, 2011: Merck Receives Health Canada Approval For Gardasil For Women Up To Age 45 45
Mar 25, 2011: FDA Approves Graceway’s Zyclara Cream For Treatment Of External Genital Warts 46
Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Number of Products Under Development for Genital Warts (Condylomata Acuminata), H2 2012 7
Products under Development for Genital Warts (Condylomata Acuminata) – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Helix BioPharma Corp., H2 2012 15
Inovio Biomedical Corporation, H2 2012 16
MediGene AG, H2 2012 17
Anaconda Pharma, H2 2012 18
Telormedix SA, H2 2012 19
Genetic Immunity, LLC, H2 2012 20
Moberg Derma AB, H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Genital Warts (Condylomata Acuminata) Therapeutics – Drug Profile Updates 35
Genital Warts (Condylomata Acuminata) Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Genital Warts (Condylomata Acuminata), H2 2012 7
Products under Development for Genital Warts (Condylomata Acuminata) – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos